The Latest Cardiac and Vascular News
Collaboration pairs AtaCor’s investigational extravascular ICD lead with Abbott’s investigational extravascular ICD system to deliver potentially life-saving therapies AtaCor plans to initiate a pivotal Investigational Device Exemption (IDE) clinical trial in 2026 to evaluate the investigational extravascular implantable cardioverter defibrillator (EV-ICD) system This initiative furthers Abbott’s leadership in advancing next-generation […]
The novel design of AtaCor’s Atala™ lead aims to provide reliable sensing, antitachycardia pacing (ATP), and shock therapies with no hardware placed in the heart or vasculature SAN CLEMENTE, Calif., Oct. 6, 2025 /PRNewswire/ — AtaCor Medical, Inc., a privately-held medical device company…
Funding Supports Regulatory Submissions and Clinical Milestones for Proprietary Extravascular (EV) Pacing & Implantable Cardioverter Defibrillator (ICD) Lead Systems SAN CLEMENTE, Calif., April 24, 2024 /PRNewswire/ — AtaCor Medical Inc., a privately-held medical device company…
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System. Building on acute data from the PASS PULL EV-ICD Study (n=18) completed in Q1-2022, the Sensing and Defibrillation with a Commercially Available ICD coupled with a Parasternal […]
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–AtaCor Medical, Inc. announced today that it has completed enrollment in its initial acute Extravascular Implantable Cardioverter Defibrillator (EV-ICD) study. Named the PASS-PULL EV-ICD Study, it is designed for acute evaluation of AtaCor’s EV-ICD lead in connection with commercially-available ICDs. Currently, when patients require ICD therapy, wires or […]
